Vivek Subbiah: Pleased to share our back-to-back papers unveiling promising results of Lurbinectedin

Hot off the press Pleased to share our back-to-back papers unveiling promising results of Lurbinectedin.

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial & exploratory translational study.

We report the activity & safety analysis of lurbinectedin monotherapy in addition to a translational exploratory analysis of endometrial molecular subtypes showing better PFS and OS in the TP53 wild-type, low/absent p53 protein immunohistochemical (IHC) and No Specific Molecular Profile (NSMP) molecular subgroups OncoAlert.

For the article: click here

Source: Vivek Subbiah / Twitter